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Project Aims

Improve the care for
patients with opioid use
disorder at PPMC through
improved utilization and
understanding of the use of
buprenorphine

Using Quality Improvement Tools
Tracking Waiver Progress

Achieve 100%
buprenorphine waiver
completion among residents
in the PPMC internal
medicine residency program

Residents with Buprenorphine Waiver

Background and Local Problem

Opioids were involved in almost
50,000 drug overdose deaths in
2019.1

Most residents at PPMC lacked a
waiver at the onset of the
program

Buprenorphine is one of
three FDA approved medical
treatments for opioid
use disorder, but providers must
apply for a waiver to prescribe it

Waivered providers were not
being tracked by the program

Arrows indicate dates of
communications sent out to
residency program

Patients needing a buprenorphine
prescription might be unable to
receive one

Gathering Baseline Understanding

• 19 out of 31 total residents
responded to a survey regarding
prior experience with the use of
buprenorphine
• Of residents surveyed, only 4 had
completed both required training
and a waiver allowing for the
prescription of buprenorphine

Timeline of Changing Legal Environment2
• 1974 – Narcotic Addict Treatment Act creates
strict regulatory environment for the use of
methadone in the treatment of opioid use
disorder
• 1989 – Language changed to apply to
broader scope of drugs used in opioid use
• 2000 – Drug Addiction Treatment Act allows
for the outpatient prescription of schedule III,
IV, and V drugs for the treatment of opioid use
disorder after completion of a waiver
• 2002 – Buprenorphine (schedule III) FDA
approved for the treatment of opioid use
disorder
• January 2021 – Trump administration
announces plan to eliminate need for waiver
• April 2021 – Biden administration reviews
policy, keeps waiver requirement while
eliminating need for training course for those
prescribing to less than 50 patients

Targeted Interventions
Residents were provided with
explicit instructions on how to apply
for a waiver, with screenshots
included as pictured below

Define – Early on in the project,
tracking buprenorphine waiver status
was identified as a measurable way to
help improve access to buprenorphine
Measure – A comprehensive review of
resident waiver status using
confirmation by DEA number on the
SAMHSA database was completed to
define and track waiver status over time
Analyze – Unwaivered residents were
asked about barriers to completing a
waiver
Improve – Targeted communications
were sent notifying residents of their
status and instructions on how to apply.
Later iterations of the communication
included screenshots of the application
process and protected time for the
application
Control – In future years, waiver
applications will be built into the intern
onboarding process to maintain waiver
status across the program
Plan, Do, Study, Act – PDSA cycles were applied over the course of the
project to help improve results in completing waivers for more residents.
Effects can be seen in the jumps in progress at the point of each
intervention.
Results and Conclusions
• In March of the 2021-22 academic year waiver completion status
had improved to 65% of residents, compared to only 19% at the
onset of the year.
• Targeted interventions, explicit instructions, and protected time
were effective in increasing the number of residents with a waiver
allowing prescription of buprenorphine.
• Next steps planned to help get additional providers waivered
include implementing the application as a part of onboarding for
new residents.
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